Impact of Advanced Glycation End Products on Endothelial Function and Their Potential Link to Atherosclerosis by Alvarez, Ezequiel et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 9
Impact of Advanced Glycation End Products on
Endothelial Function and Their Potential Link to
Atherosclerosis
Ezequiel Alvarez, Beatriz Paradela-Dobarro,
Mercedes González-Peteiro and
José Ramón González-Juanatey
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.73025
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Ezequiel Alvarez, Beatriz Paradela-Dobarro, 
Mercedes González-Peteiro and 
José Ramón González-Juanatey
Additional information is available at the end of the chapter
Abstract
The role of advanced glycation end products (AGEs) in cardiovascular diseases is a matter 
of interest in the last years and the strong association between the action of AGEs on 
their receptor (RAGE) and atherosclerosis has attracted increased attention. The aim 
of this chapter is to review the results of our laboratory and others on the molecular 
mechanisms triggered by AGEs in the endothelium that could participate in the ath-
erosclerotic process. These mechanisms and molecular pathways could be the source 
of new therapeutic targets against atherosclerosis or vascular disease. Oxidative stress 
in endothelium induced by AGEs triggers molecular signaling pathways that produce 
an inflammatory response or even endothelial dysfunction. Adhesion molecules expression 
at the membranes of endothelial cells as a consequence of this response or induced by 
other mechanisms involving AGEs mediates the adhesion of leukocytes to endothelium. 
This adhesion is a key step in the atherogenesis process and the possible involvement 
of AGE-RAGE axis in this process should be considered as a potential therapeutic tar-
get. Finally, potential pharmacological modulation of AGE-RAGE axis activity at the 
endothelium is suggested, but the specific pharmacological tools available nowadays are 
missing; respectively, drugs used for the treatment of cardiovascular and metabolic dis-
eases could be helpful for AGE-RAGE axis modulation, thus also affecting endothelial 
(dys)function.
Keywords: advanced glycation end products, atherosclerosis, endothelial dysfunction, 
oxidative stress, receptor for advanced glycation end products, vascular adhesion 
molecules, vascular inflammation
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1. Introduction
Cardiovascular diseases resulting from atherosclerosis have become the most important cause 
of mortality and morbidity in the general population [1]. Although atherosclerosis develops 
as a consequence of multiple risk factors such as hypertension, dyslipidemia, diabetes, aging 
and smoking, the common pathway for its development is endothelial dysfunction and vas-
cular inflammation [2]. In the last two decades, the role of advanced glycation end products 
(AGEs) in the development of endothelial dysfunction has gained increasing interest [3–5], 
initially as a possible molecular mechanism of diabetic cardiovascular complications [3], and, 
in the last years, as an independent risk factor of vascular injury [6].
AGEs are products of non-enzymatic molecular modifications of proteins and lipids that 
affect the structure and function of the target molecule. They are produced endogenously by 
spontaneous reactions, but pathophysiological conditions may accelerate their formation and 
they also contribute to disease by different mechanisms.
AGEs comprise a heterogeneous group: the most studied are pentosidine and Nε-carboxymethyl-
lysine (CML) and quantitatively, the most important in the tissues are the hydroimidazolones 
like CML [7]. AGEs are formed by a combination of glycation, oxidation, and/or carbonylation 
reactions both in the extra- and in the intracellular space. Other processes involving lipid per-
oxidations in the cell membranes lead to the formation of advanced lipid end products, as for 
example, malondialdehyde [8]. The classical mechanism of AGE formation is the slow Maillard 
reaction between glucose or reducing sugars and proteins [9]. The interaction between the car-
bonyl groups of reducing sugars and amino groups of proteins results in the formation of a 
Schiff base within a few hours. Intramolecular rearrangement of the Schiff base results in more 
stable Amadori products [9]. An example of these types of products is glycated hemoglobin or 
glycated albumin, the former is widely used in clinical practice for diagnosis and follow-up of 
diabetes mellitus and the last could be regarded as a smart alternative to modified hemoglo-
bin for the same purposes, with less dependence on hematological diseases and intracellular 
conditions. Finally, the process of oxidation of the Amadori products leads to reactive carbonyl 
compounds and subsequently to the formation of AGEs within weeks to months. AGEs can 
also be formed intracellularly. Glucose is altered into reactive carbonyl compounds during 
glycolysis pathway, of which the best-known is methylglyoxal. The chemical reaction between 
these carbonyl compounds and proteins can result in AGEs [10].
Absorption of exogenous AGEs also contributes to their accumulation in tissues. Tobacco 
smoke contains highly reactive glycation products which rapidly form AGEs in vitro and in vivo 
and therefore, increase the serum AGEs levels in smokers compared to non-smokers [11]. The 
content of AGEs in food depends on the temperature at which food products are prepared, with 
oven frying being the most severe inducer [12]. Approximately 10% of the ingested AGEs are 
absorbed from the gastrointestinal tract into the blood [13]. The final level of AGEs accumula-
tion depends on their clearance and the metabolic mechanisms by the kidney and liver, respec-
tively. Increased level of AGEs can be found in patients with either renal [13] or liver failure [14].
The role of AGEs in cardiovascular diseases is a matter of interest in the last years [15], and 
the strong association between the axis of action of AGEs and their receptor (RAGE) and 
atherosclerosis or cardiovascular ischemic disease [3, 16, 17] has attracted increased attention. 
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The aim of this chapter is to review the results of our laboratory and others on the molecular 
mechanisms triggered by AGEs in the endothelium that could participate in the atheroscle-
rotic process. These mechanisms and molecular pathways could help in the development of 
new therapeutic targets against atherosclerosis or vascular disease.
2. Molecular mechanisms triggered by AGEs in the endothelium
It is generally accepted that AGEs target cells by three main mechanisms. First, proteins modi-
fied by AGEs have altered biological function, either enzymatic activity, binding properties or 
structural conformation. Second, extracellular matrix components modified by AGEs interact 
abnormally with other matrix components and with matrix receptors, such as integrins. This 
includes also the formation of new links or the alteration of those previously existing, between 
proteins, which may alter the physical properties of extracellular matrix and cell environ-
ment. Third, plasma proteins modified by AGEs bind to cell surface receptors, of which the 
receptor for AGEs (RAGE) is acknowledged to be the most important, activating intracellular 
signaling pathways and various cellular responses.
Binding of AGEs to RAGE is responsible for the generation of reactive oxygen species (ROS) 
and the activation of transcription factors such as nuclear factor-κB (NF-κB), with subsequent 
changes in the expression of many genes involved in vascular inflammation and endothe-
lial dysfunction [18–20]. Besides from the involvement of AGEs-RAGE axis, the precursors of 
AGEs, like Amadori products or early glycated products also have a role in the global response 
of non-enzymatic glycation of proteins, so we will also discuss their effects on endothelial cells.
2.1. AGEs-induced ROS production in the endothelium
One of the first and best studied actions of AGEs on endothelial cells is the induction of ROS. The 
suggested mechanisms for this action are several and range from the activation of ROS-producing 
enzymes to the reduction of ROS-neutralizing enzymes. In the first group of enzymes or enzyme 
complexes are nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [21] and mito-
chondria [22], whereas in the second, there are endothelial nitric oxide (NO) synthase (eNOS) 
[23], superoxide dismutase (SOD) and glutathione peroxidase [24, 25]. The molecular mecha-
nisms of these actions have been related to the activation of NF-κB via RAGE [26, 27].
ROS production in endothelial cells has important consequences on endothelial activation. In 
brain microvascular endothelial cells, AGEs-induced ROS production enhances vascular endo-
thelial growth factor (VEGF) expression, which mediates an increase in cell permeability [28], 
and platelet tissue factor up-regulation [29]. Other mechanisms of AGEs on endothelial cells 
promoting endothelial activation or dysfunction are the generation of asymmetric dimethylargi-
nine (ADMA, a metabolic by-product of natural protein modification processes in the cytoplasm 
of cells, that acts as a competitive inhibitor of NOS) [30], or impaired calcium signaling [31].
It is important to note that the effects of AGEs’ precursors (i.e. Amadori products or glycated 
proteins) on endothelial cells, differ from the effects of AGEs themselves. Several works 
have focused on this issue (see, for a review, [32]). Amadori products modify eNOS activ-
ity and gene expression, promoting apoptosis of endothelial cells [33, 34]. A recent study 
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performed by our group has highlighted the important molecular and functional differ-
ences between early glycated human serum albumin (gHSA) and advanced glycated albu-
min (AGE-HSA), obtained commercially or by glucose incubation during 4 weeks at 37°C 
in aseptic conditions, respectively [35]. The respective control molecules of these treatments 
were unmodified commercial HSA and HSA incubated for the same time than AGE-HSA, 
but without glucose (Ct-HSA). Molecular characterization of the early and advanced glyca-
tion products formed on each modified albumin (gHSA and AGE-HSA) were studied by 
matrix assisted laser desorption/ionization—time of flight (MALDI-TOF)-mass spectrom-
etry. Once characterized, the effects on ROS production of human umbilical vein endothelial 
cells (HUVECs) under the stimuli of gHSA or AGE-HSA were compared [35]. Low concen-
trations of gHSA enhanced long-lasting ROS production in HUVECs, whereas AGE-HSA 
induced extracellular ROS production after short time of incubation and at lower concentra-
tions than gHSA. Extracellular ROS production of HUVEC was measured by the cytochrome 
C reduction method, whereas intracellular ROS production of HUVEC was measured by 
5(6)-carboxy-2′,7′-dichlorofluorescein diacetate (cDCF-DA; Sigma-Aldrich), an intracellular 
dye for that purpose [36].
Treatment of HUVECs with gHSA (25–100 μg/mL) for different times (4–12 h) induced sig-
nificant increments of extracellular ROS production with respect to treatment with the same 
concentration of un-modified albumin (HSA, used as control) [36]. The maximal response 
(i.e. the quantity of ROS) was obtained with 25 μg/mL gHSA after 4 h of treatment (Figure 1a). 
The effects of AGE-HSA were studied under the same conditions. AGE-HSA increased the 
extracellular ROS production at lower concentrations (12 μg/mL) and after shorter time of 
exposure than gHSA (2 h). Another important difference is that, at long incubation periods, 
the ROS-inducing effects of gHSA were maintained, whereas no significant increases on ROS 
production were observed with AGE-HSA at 4–8 h (Figure 1b).
Similar experiments were designed to measure the intracellular ROS production by using 
cDCF-DA after 4 h of treatment the HUVECs with gHSA or AGE-HSA (12–50 μg/mL). 
Figure 1. Extracellular ROS production in HUVECs after treatment with different concentrations of (a) gHSA (12–50 mg/
mL) or (b) AGE-HSA (12–50 mg/mL), for periods of time indicated on each graph. Columns represent the ratio of ROS 
produced by treatment/HSA and are expressed as mean ± S.E.M. (vertical bars) of at least three independent experiments. 
*p < 0.05 with respect to the control values (Student’s t test).
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Interestingly, at 25 μg/mL, gHSA significantly enhanced the intracellular ROS production, 
whereas AGE-HSA only showed a trend to slightly increase it (Figure 2).
Therefore, differences in the induction of ROS production were observed between gHSA (a low 
glycated product) and AGE-HSA (a high glycated product). Although the effects of AGE-HSA 
are accepted to be mediated by RAGE, the receptor that mediates the effects of gHSA has not 
been revealed yet [37], since, the effects of gHSA are not mediated by RAGE [38].
2.2. Expression of adhesion molecules mediating leukocyte adhesion to 
endothelium
RAGE-ligands interaction induces a series of signal transduction cascades and lead to the acti-
vation of transcription factor NF-κB as well as increased expression of cytokines, chemokines, 
and adhesion molecules [39]. Expression of inducible adhesion molecules is a final common 
pathway in the development of vascular inflammation and pathology, rendering the vascula-
ture a selective target for circulating peripheral blood cells [27, 40].
A number of studies have demonstrated induction of vascular cell adhesion molecule-1 (VCAM-1) 
expression in a RAGE-dependent manner when endothelial cells are exposed to AGEs [18]. 
Moreover, engagement of RAGE by AGEs results in enhanced expression of other adhesion mole-
cules, such as E-selectin and intercellular cell adhesion molecule-1 (ICAM-1) [40–42]. High expres-
sion of adhesion molecules in endothelial cells may promote adhesive interactions of circulating 
monocytes with the endothelial surface, resulting, eventually, in transendothelial migration [43].
We confirmed that AGE-HSA up-regulated ICAM-1 and VCAM-1 expression more than 
gHSA, in terms of mRNA quantitative changes, measured by total messenger RNA retro-
transcription and quantitative real-time polymerase chain reaction (qPCR) [35]. Even while 
Figure 2. Intracellular ROS production in HUVECs after 4 h of treatment with different concentrations of gHSA (white 
columns) and AGE-HSA (black columns), as indicated in the x-axis. Results are shown as the ratio modified HSA/control 
HSA, expressed as mean, in columns, ± S.E.M. (vertical bars) of at least four independent experiments. Comparisons 
were made between each ratio level and the unit (*p < 0.05; Student’s t test).
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the effects of gHSA seemed to be limited to 4 h- treatment, AGE-HSA up-regulated VCAM-1 
and ICAM-1 expression for longer periods of time (from 2 to 6 h). Differences on the active 
concentrations of both glycation products were also observed: whereas gHSA was only active 
at 25 μg/mL, AGE-HSA was also effective at 12 and 100 μg/mL (Figure 3).
To further confirm the increase in the expression of these adhesion molecules, protein levels of 
VCAM-1 and ICAM-1 were analyzed by western blot analysis after the treatment of HUVECs 
with two relevant concentrations of gHSA and AGE-HSA: 25 and 100 μg/mL, in comparison 
with the same concentrations of unmodified HSA and Ct-HSA, respectively. There was a 
significant elevation of VCAM-1 and ICAM-1 levels caused by the effect of both AGE-HSA 
concentrations tested. On the other hand, only the concentration of 25 μg/mL gHSA (but not 
100 μg/mL) enhanced the ICAM-1 protein levels (Figure 4).
The functional translation of VCAM-1 and ICAM-1 up-regulation was analyzed by the adhesion 
of peripheral blood mononuclear cells (PBMCs) to HUVEC monolayers after treatment with both 
types of modified albumins for 4 h (Figure 5). After these treatments, the adhesion of calcein-
AM-stained PBMCs to HUVEC monolayers after 1 h of incubation and washing of non-adhered 
Figure 3. The expression levels of mRNA of VCAM-1 (a and c) and ICAM-1 (b and d) after treatment with gHSA or AGE-
HSA at the concentrations and times indicated on HUVEC cultures. Results are shown as the ratio treatment/respective 
control, expressed as mean (columns) ± S.E.M. (vertical bars) of at least four independent experiments. Comparisons 
were made between each ratio level and the unit (*p < 0.05; Student’s t test) and between AGE-HSA and gHSA treated 
experiments ate the same time of incubation (a and b) or concentration (c and d; #p < 0.05; Student’s t test).
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PBMCs was quantified by fluorescence. In these conditions, gHSA (25 μg/mL) induced no signifi-
cant effect in PBMCs adhesion in comparison with the control HSA. However, AGE-HSA (25 μg/
mL) induced a significant increase in the adhesion of PBMC to HUVEC monolayers.
The effects of gHSA and AGE-HSA on PBMCs transmigration through HUVEC monolayers 
were studied in comparison to the ICAM-1 and VCAM-1 changes of expression. For these 
experiments HUVEC with transfected green fluorescent protein were grown until confluence 
onto transwells with 5 μm of pore size (Millipore). After treatment with AGE-HSA (25 and 
100 μg/mL) for 4 h PBMCs were layered over the HUVECs and incubated at 37°C. TNF-α 
(10 ng/mL) was used as a positive control because it induces endothelial cell activation and 
promotes PBMCs transmigration through the endothelial monolayer. The number of trans-
migrated PBMCs were estimated by quantification of nuclei acids content with CyQUANT® 
GR dye (Molecular probes, Invitrogen) at the end of the experiment. Unless for the case of 
TNF-α, no changes were observed for any of the stimuli after 3 h of treatment. However, after 
24 h of HUVEC incubation with 25 μg/mL AGE-HSA, a significant increase in the migration 
of PBMCs was observed as compared to control (Figure 6). On the contrary, higher concentra-
tion of AGE-HSA (100 μg/mL), showed no effect in the transmigration of PBMCs. The positive 
control with TNF-α increased the migration of PBMCs even more than after 3 h (Figure 6).
Figure 4. The expression levels of VCAM-1 and ICAM-1 measured by western blot in HUVEC protein extracts obtained 
after 4 h of treatment with gHSA or AGE-HSA (25 or 100 μg/mL, as indicated). TNF-α (10 ng/mL) was used as a positive 
inducer control. (a) Representative blots for VCAM-1, ICAM-1 and β-actin. Columns represent the fold change of protein 
expression for (b) VCAM-1 and (c) ICAM-1 calculated by optical densitometry with respect to β-actin and expressed 
as mean values (columns) ± S.E.M. (vertical bars) of at least three independent experiments. *p < 0.05 with respect to 
unmodified HSA or Ct-HSA for gHSA and AGE-HSA, respectively (Student’s t test).
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Given the results obtained in the adhesion molecules expression in HUVECs, another approach 
was performed repeating the study with in vivo glycated albumin obtained from healthy volun-
teers and from cardiovascular patients, which donated their blood after signing informed consent. 
Figure 5. Quantification of the adhesion of PBMCs to a HUVEC monolayer, after treatment of HUVECs during 4 h 
with gHSA (25 μg/mL) or AGE-HSA (25 μg/mL), compared with HSA (25 μg/mL) or ct-HSA (25 μg/mL), respectively. 
The graph represents the mean percentage of adhesion (columns) ± S.E.M. (vertical bars) of at least three independent 
experiments. *p < 0.05 between the columns indicated (ANOVA followed by Tukey’s test).
Figure 6. Transmigration of PBMCs through HUVEC monolayers after 3 h (white columns) or 24 h (black columns). 
Columns represent the mean (columns) ± S.E.M. (in vertical bars) of the increase of PBMCs transmigration after treatment 
compared to untreated control. *p < 0.05 with respect to untreated control (Student’s t test).
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The whole study and protocols were approved by the Ethics Committee for Human Studies at 
Galicia (Spanish region) in accordance to the 1975 Declaration of Helsinki. Particularly, we ana-
lyzed the effect of HSAs categorized in healthy or nonglycated (from healthy volunteers), low-
AGE or high-AGE (from cardiovascular patients), according to their content in AGE adducts. 
Glycation level was estimated by the molecular weight increment of isolated HSAs, due to the 
incorporation of different glycation products to the molecule. This was measured by mass spec-
trometry with a 4800 MALDI-TOF/TOF analyzer (Applied Biosystems). On this basis, attending 
to the increase of HSA molecular weight with respect to non-modified HSA, three stocks of HSA 
were prepared and categorized as healthy-nonglycated HSA, low-, and high-AGE HSA (molecu-
lar weights of 66,481, 66,665 and 66,778 Da for healthy, low-, and high-AGE HSA, respectively). 
HUVECs were incubated with a range of concentrations of these types of HSAs (12–200 μg/mL) 
for 4 h. In these conditions, the treatment with high-AGE HSA significantly increased the mRNA 
expression of ICAM-1 at concentrations of 12.5 and 25 μg/mL with respect to healthy-nongly-
cated HSA (Figure 7a; p < 0.001). An increase was also observed at 100 μg/mL concentration with 
respect to healthy HSA (p = 0.046). Moreover, high-AGE HSA was able to induce a significant 
increase with respect to low-AGE HSA at 12.5 and 25 μg/mL (Figure 7a; p < 0.05).
In the case of VCAM-1 expression, high-AGE HSA only induced an increase in the mRNA 
expression at 12.5 μg/mL with respect to healthy HSA and low-AGE HSA (Figure 7b; p < 0.05). 
At this concentration, low-AGE HSA also induced an increase in the expression of VCAM-1 
with respect to healthy HSA (Figure 7b; p < 0.05). Finally, at a concentration of 50 μg/mL, 
high-AGE HAS induced a reduction in the expression of VCAM-1 with respect to healthy 
HSA (p < 0.05). This reduction in the expression of VCAM-1 was only transient as the mRNA 
levels recovered again at higher concentrations. Altogether, these results suggest that in vivo 
glycation of albumin could have a pro-inflammatory effect in endothelial cells, which would 
trigger chronic endothelial dysfunction.
PBMCs adhesion to HUVECs was also studied with in vivo glycated albumins at 12.5, 25 and 
100 μg/mL. HUVECs were treated with these concentrations for 24 h. After that, HUVECs 
Figure 7. The expression of mRNA for ICAM-1 (a) and VCAM-1 (b) after the treatment of HUVECs with HSA isolated 
from healthy volunteers (healthy HSA) or with low-AGE HSA and high-AGE HSA from cardiovascular patients 
for 4 h. Columns represent the fold increase of mRNA expression for each gene and are expressed as mean values 
(columns) ± S.E.M. (vertical bars) of at least three independent experiments. *p < 0.05 with respect to healthy HSA. 
#p < 0.05 with respect to low-AGE HSA (Student’s t test).
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were incubated with PBMCs for 1 h. A slight but significant increase in PBMCs adhesion (mea-
sured as explained above) was observed with high-AGE HSA with respect to low-AGE HSA at 
12.5 μg/mL (p < 0.05), but not with respect to healthy HSA (Figure 8; p < 0.05). A trend toward 
an increase in PBMCs adhesion was also observed after treatment with high-AGE HSA with 
respect to low-AGE HSA at 25 μg/mL (p = 0.06). This suggests that in vivo glycated albumin 
needs more time to induce PBMCs adhesion than highly in vitro glycated albumin (AGE-HSA).
3. Potential implications for pharmacological modulation of AGE-
RAGE axis activity
In an attempt to counteract the inflammatory effects of AGE-HSA, we selected three RAGE 
inhibitors: a soluble form of RAGE (sRAGE; R&D systems), used at 0.25, 0.5 and 1 ng/mL; 
a monoclonal antibody against RAGE (anti-RAGE; R&D systems), used at 5, 10 and 20 μg/
mL; and the RAGE antagonist FPS-ZM1 (Calbiochem, Merck Millipore), used at 125, 250, 500 
and 1000 nM. HUVECs were pre-treated with different concentrations of these inhibitors and 
50 min later treated with 25 μg/mL AGE-HSA. The inhibitory effect of these agents on the 
expression of VCAM-1 and ICAM-1 in HUVECs was studied.
However, contrary to what we expected, blockade of RAGE by using sRAGE, anti-RAGE anti-
body and FPS-ZM1 was not sufficient to counteract the AGE-induced VCAM-1 and ICAM-1 
up-regulation at any of the concentrations tested under our experimental conditions. Our 
results may suggest that on endothelium, other RAGE-independent mechanisms may also 
Figure 8. PBMCs adhesion to HUVEC monolayers treated with albumin from healthy volunteers (healthy HSA) or low-
AGE HSA and high-AGE HSA from cardiovascular patients for 24 h. Columns represent the fold change of percentage 
of PBMCs adhered with respect to commercial HSA, expressed as mean values (columns) ± S.E.M. (vertical bars) of at 
least three independent experiments. #p < 0.05 with respect to low-AGE HSA (Student’s t test).
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be acting to increase adhesion molecule expression and induce inflammation. Other possi-
ble explanation for these results is that the pharmacological tools actually available to block 
RAGE activity are not able to block the effects of AGEs at the endothelial level. However, the 
results obtained on in vivo models of disease are promising, as we comment below.
To investigate the effects of RAGE blockade in pathological conditions, many studies have used 
soluble forms of RAGE or anti-RAGE antibodies, which can antagonize RAGE-ligand interaction 
to competitively inhibit the activation of RAGE signaling [39, 44, 45]. Evidence from these stud-
ies has shown that RAGE blockade protected against various disease challenges. Soluble RAGE, 
which competes with cellular RAGE for ligand binding, has been able to reduce inflamma-
tory responses in several models tested. Streptozotocin-induced diabetic apoE−/− mice treated 
with once daily injections of murine sRAGE showed suppressed acceleration of atherosclerotic 
lesions in a dose-dependent manner [46]. In parallel with decreased atherosclerotic lesion area 
and the complexity of the atheroma plaque composition, the levels of tissue factor, VCAM-1, 
AGEs, and nuclear translocation of NF-kB were decreased in the aortas of sRAGE-treated mice 
[42, 46]. In other work, sRAGE-treated mice displayed significant stabilization of the lesion area 
at the aortic root. Compared with diabetic mice receiving albumin (placebo), those receiving 
sRAGE had significantly diminished activity of monocyte chemoattractant protein-1 (MCP-1), 
cyclooxygenase-2 (COX-2), VCAM-1 and matrix metalloprotease 9 (MMP-9) within aortic tis-
sue [47]. Similarly, administration of sRAGE resulted in a highly significant decrease in athero-
sclerotic lesion area in parallel with decreased vascular expression of pro-inflammatory RAGE 
ligand S100/calgranulins and VCAM-1 and MMPs [48]. Moreover, sRAGE-treated non-diabetic 
mice displayed significantly decreased atherosclerosis and vascular inflammation [47, 48].
Further studies using anti-RAGE IgG fragments to block ligand binding to RAGE have con-
firmed these results, especially at the highest dose (up to 10 μg/mL) tested [49]. Exposure 
of HUVECs to AGE-bovine serum albumin induced expression of VCAM-1 and increased 
adhesiveness of the monolayer for T lymphoblast of the Molt-4 cell line, which was inhibited 
by addition of anti-RAGE IgG or sRAGE [40]. Activation of signaling pathway on endothelial 
cells by advanced oxidation products resulted in overexpression of VCAM-1 and ICAM-1 at 
both, gene and protein levels, something that was prevented by blocking RAGE with either 
anti-RAGE IgG or excess sRAGE [27]. Administration of anti-RAGE IgG or sRAGE strongly 
blocked the increase in vascular permeability in diabetic rats injected with human diabetic 
red blood cells [50]. Mice treated with sRAGE or anti-RAGE F(ab’)2 fragments displayed sig-
nificantly lower intima/media ratio (a marker of negative vascular remodeling after injury) 
compared to vehicle-treated animal models of femoral artery injury [51]. However, despite the 
fact that both, sRAGE and anti-RAGE IgG were able to reduce inflammatory responses in all 
models tested so far [42, 46, 50, 52], no significant decrease in ICAM-1 and VCAM-1 expres-
sion was observed after pre-treatment with soluble RAGE or anti-RAGE antibody, under our 
experimental conditions.
A recently developed high-affinity RAGE-specific inhibitor: FPS-ZM1 (N-benzyl-4-chloro-
N-cyclohexylbenzamide; Calbiochem, Merck Millipore) [53] was also studied. This inhibitor 
was developed to interact with the ligand-binding domain of the receptor and block RAGE 
signaling. In our in vitro experimental conditions this approach was also unable to inhibit 
AGE-induced VCAM-1 and ICAM-1 up-regulation.
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It is worth mentioning that, most of the above-mentioned works did not elucidate the precise 
AGE(s) that trigger signal transduction mechanisms upon interacting with RAGE. Kislinger 
et al. [54] studied the effect of CML-adducts and showed that CML-mediated VCAM-1 
expression on HUVECs was also suppressed in the presence of excess sRAGE or anti-RAGE 
IgG. Nevertheless, they suggest that the findings presented in their work do not rule out other 
specific AGE products of glycation or oxidation, such as pentosidine, pyralline, methylgly-
oxal, and imidazolone [55–57], which are present in our modified albumins. Additionally, 
they also specified that their findings do not rule out either the presence of other receptors or 
cellular interaction sites for CML adducts, being possible that other receptors for AGE [58–60] 
may also engage CML- and AGE-modified adducts. These situations might explain why no 
reduction in the up-regulation of adhesion molecules is observed after pre-treatment with 
sRAGE and anti-RAGE antibody under our experimental conditions.
Additionally, Amadori-modified albumin stimulates adhesion of monocytes to endothelial cells 
through enhanced transcription of the cell surface adhesion molecules E-selectin, VCAM-1 and 
ICAM-1 [61], implicating an initial endothelial cell activation occurring at atherosclerosis-prone 
vascular sites [62, 63]. However, Amadori products do not compete with AGE-albumin for 
binding to AGE receptors such as RAGE [64]. Aortic endothelial cells express specific receptors 
for Amadori-modified albumin [37, 65]. Although less information is available for the recep-
tor for Amadori products and signaling through Amadori-modified albumin receptors remains 
obscure, calnexin [66] and nucleophosmin [67, 68] have been reported to be the fructosyl-lysine 
specific binding proteins [66–68]. Binding of Amadori-modified albumin to calnexin-like recep-
tors may participate in degradation and/or activation of signal transduction processes involved 
in mediating the biologic activities of Amadori-modified albumin [66]. The E-selectin expression 
induced by Amadori-modified albumin was 10 or 20 times higher than that induced with three 
types of AGEs-HSAs and was not suppressed by anti-RAGE antibody [69]. This would explain 
why RAGE antagonism would not counteract the increase in adhesion molecules expression.
In agreement with this hypothesis, Esposito et al. [70] found that anti-RAGE antibody com-
pletely prevented leukocyte adhesion to endothelial cells grown for 8 weeks in high-glucose-
containing media, but it did not reduce the adhesion at 24 h. These results demonstrate that 
AGEs are important mediators of high-glucose-induced endothelial dysfunction after long-
term exposure, whereas the same changes in acute exposure occur with the action of media-
tors other than AGEs. As the formation of Amadori products is highly probable after 24 h 
incubation in high glucose medium, but not the formation of AGEs, the effects on the inflam-
mation parameters observed by Esposito et al. [70], and not prevented by anti-RAGE antibod-
ies, might be due to the effect of the early glycated products, and not AGEs.
Besides from directly blocking RAGE, alternative pharmacological approaches might turn 
out to be more promising. Namely, it has been shown that both RAGE and sRAGE can be 
regulated by currently available pharmacological agents [71]. Other drugs currently in use 
for diabetic complications have been shown to have an effect on AGE accumulation. These 
include the antihypertensive angiotensin-converting enzyme inhibitor (ACEI) ramipril [72] 
and the glucose-lowering drug metformin [73], which both reduce AGE. Forbes et al. [74] dem-
onstrated that compared with placebo, the ACEI perindopril increased human plasma sRAGE 
levels and reduced plasma AGE concentrations, suggesting an additional mechanistic effect of 
ACE inhibition in the treatment and prevention of vascular disease. The inhibition of ACE in 
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rats increased the renal expression of sRAGE and decreased the expression of renal full-length 
RAGE protein [74]. These investigators also showed that plasma sRAGE levels were signifi-
cantly increased by inhibition of ACE in both diabetic rats and human subjects with type 1 
diabetes [74]. Olmesartan, an angiotensin II type 1 receptor blocker, inhibited the AGE-evoked 
ROS generation and reduced the expression levels of monocyte chemoattractant protein 1 and 
ICAM-1 in endothelial cells, subsequently blocking T-cell adhesion to endothelial cells [75].
Other potential agents that may affect circulating sRAGE include the thiazolidinediones 
[76, 77] and statins [78–80], both of which are known to modulate AGE-RAGE axis. Marx et al. [76] 
investigated the effects of the two thiazolidinediones available, rosiglitazone and pioglitazone, 
on RAGE expression in HUVECs. Exposure of HUVECs to thiazolidinedione resulted in a simi-
lar reduction in RAGE mRNA expression, via inhibition of NF-κB activation, and in RAGE cell 
surface expression, demonstrating how these drugs may influence RAGE expression and its del-
eterious inflammatory activity in subjects with DM [76]. Blockade of the interaction of S100A12 
(an endogenous ligand of RAGE) with RAGE by statins at an early stage may prevent inflam-
mation in atherosclerosis and counteract the harmful effects mediated by C reactive protein [81].
Finally, recent results testing new potential drugs have been reported. Curcumin, a poly-
phenolic natural compound is able to trap methylglyoxal, an important precursor of AGEs 
[82]. Added on endothelial cell cultures curcumin reduced the intracellular ROS levels and 
improved cell viability compared with the treatment of methylglyoxal alone. There was also 
a significant reduction in the expression levels of ICAM-1 [82]. Liquiritin, the 4’-O-glucoside 
of the flavanone liquiritigenin, reduced AGEs-induced apoptosis and ROS generation in 
HUVECs and also significantly increased AGEs-reduced SOD activity [83]. It even down-
regulated the RAGE protein expression and significantly blocked NF-κB activation [83].
4. Conclusions
Oxidative stress induction by AGEs at endothelium triggers molecular signaling pathways 
that produce an inflammatory response or even endothelial dysfunction. Adhesion molecules 
expression at the membrane surface of endothelial cells as a consequence of this response or 
induced by AGEs by other mechanisms mediates the adhesion of leukocytes to endothelium. 
This adhesion is a key step in the atherogenesis process and the possible involvement of 
AGE-RAGE axis in it should be considered as potential therapeutic target. Finally, possible 
pharmacological modulation of AGE-RAGE axis activity at the endothelium is suggested, 
but specific pharmacological tools available nowadays are not efficient enough; momentarily, 
drugs used for cardiovascular and metabolic problems could be helpful in modulating the 
AGE-RAGE axis.
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